ArticleArchives of osteoporosis2026
Longitudinal bone loss in patients with stage 3 CKD: a study based on densitometry and HR-pQCT.
Article in Archives of osteoporosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a 1-year longitudinal study of 34 patients with stage 3 CKD and stable bone turnover markers there was no deterioration of bony quality. However, HR-pQCT identified impaired bone density in 73.5% of cases at baseline, which was undetected by DXA. Findings suggest early skeletal involvement despite stable renal function. PURPOSE: It has been postulated that chronic kidney disease (CKD) is associated with bone loss. However, prospective data are limited, and it remains unclear whether bone loss or microarchitecture chances occurs in the early stages of CKD with stable renal function.
methodsIn this longitudinal cohort study, patients with stage 3 CKD underwent dual-energy X-ray absorptiometry (DXA) and high-resolution peripheral quantitative computed tomography (HR-pQCT), with reassessment after 1 year. Bone biomarkers, including alkaline phosphatase, intact parathyroid hormone (iPTH), intact fibroblast growth factor-23 (iFGF-23), total procollagen type 1 N-terminal propeptide (tP1NP), and β-isomerized C-terminal telopeptide of type I collagen -I (β-CTX-I) were also measured.
resultsThirty-four patients were included (51 ± 3 years, 44% men). Bone turnover markers remained stable during follow-up. Osteopenia and/or osteoporosis at one or more sites was found in 45.5% of participants. Low bone mineral density (BMD), T-score < -1, was observed in 32.3% (lumbar spine), 29.4% (total hip), 14.7% (1/3 distal radius), and 26.5% (ultradistal radius). HR-pQCT revealed impaired BMD in at least one site (tibia or radius) in 73.5% of cases. Renal function remained stable during follow-up, with no significant changes in bone biomarkers. DXA showed a slight but significant decline in T-scores at the total hip and 1/3 distal radius, whereas HR-pQCT parameters remained unchanged.
conclusionIn patients with stage 3 CKD and stable renal function, bone microarchitecture identified impaired BMD not fully detected by DXA. Over 1 year, however, only minimal changes in bone parameters were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.